



Technical Director: Jessica Freedman, RVT
 Peter J Higgins, MD
 John F Moloney, MD
 John C Lualdi, MD
 Karen Kurkjian, MD



Vascular Test	Journal/Society Reference	Screening Indications	Clinical Trial Participation
<p>Abdominal Aortic Ultrasound</p>	<p>USPSTF Annals of Internal Medicine volume 142, pages 198-202 and pages 203-211</p> <p>ACC/AHA PAD Guidelines: JACC 2006</p>	<ol style="list-style-type: none"> Men > 60 years old with a family history of AAA Men 65 - 75 who are current or former smokers 	
<p>Renal Artery Ultrasound</p> <p>Renal Duplex is well validated, the least expensive testing and requires no radiation, contrast, or gadolinium. Both CCM's and MCA's labs were reviewed by the CORAL Trial ultrasound core lab and given high marks. Both labs are allowed to participate in the ultrasound sub-study.</p>	<p>ACC/AHA PAD Guidelines: JACC 2006</p> <p>CORAL Entry Criteria (#8 in next column***)</p>	<ol style="list-style-type: none"> HTN < 30 years old Severe HTN after age 55 Accelerated or Resistant HTN (not at goal after 3 meds) Malignant HTN (Renal failure, CHF, HA, Retinopathy) Worsening renal function after ACEI/ARB Unexplained worsening renal function Unexplained CHF HTN on 2 meds*** 	<p>CORAL Trial: NIH sponsored trial comparing med RX with renal artery stenting. MMC co-PI's are Mark Parker at Maine Nephrology and Peter Higgins.</p>
<p>Carotid Ultrasound</p>	<p>American Society of Neuroimaging and Society of Vascular and Interventional Neurology Journal of Neuroimaging 2007;17:19-47</p>	<ol style="list-style-type: none"> Age ≥ 65 with ≥ 3 risk factors Patient is undergoing CABG Symptomatic PAD 10 years after radiation therapy of the head and/or neck After carotid endarterectomy History of retinal ischemic events 	<p>CAPTURE: Symptomatic and asymptomatic patients with carotid stenosis at high risk for CEA receive a carotid stent</p>
<p>Lower Extremity Arterial Evaluation: Resting ABI, exercise ABI, and/or lower extremity duplex</p> <p>Goal of screening asymptomatic patients is to identify vascular disease to set cholesterol goals and antiplatelet therapy. Framingham Risk Score doubles if abnormal ABI is included.</p>	<p>ACC/AHA PAD Guidelines: JACC 2006</p>	<ol style="list-style-type: none"> Symptoms: typical and atypical. Abnormal physical exam Age < 50 with DM and one risk factor Age 50 - 69 with DM or smoking history All age 70 or greater Vascular disease in another distribution 	<p>CLEVER Trial: Compares iliac stent placement to supervised exercise using Turning Point. Includes long total occlusions.</p> <p>ACCELA Trial: Tests new, novel anti-claudicant verses both placebo and cilostazol.</p>

96 Campus Drive, Suite 1 · Scarborough, ME 04074 · 207-885-9905 · FAX: 207-396-5600

www.heartmaine.com